AbstractBySubCategory

ABSTRACT TITLE FIRST AUTHOR ABSTRACT NO.sort descending
Intravesical rad-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study. Stephen A. Boorjian

279

BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer. Emma Hall

280

Muscle-invasive bladder cancer: Molecular subtypes and response to neoadjuvant chemotherapy. Roland Seiler

281

Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. David J. Vaughn

282

Results of a randomised phase II study of hypofractionated bladder radiotherapy (RT) with or without image guided adaptive planning (HYBRID - CRUK/12/055). Robert Anthony Huddart

283

Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from the total KEYNOTE-052 study population. Arjun Vasant Balar

284

A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Joaquim Bellmunt

285

Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma. Thomas Powles

286

Subtyping muscle-invasive bladder cancer to assess clinical response to trimodality therapy. Jason A. Efstathiou

287

Long-term incidence of venous thromboembolic events following cystectomy: A population-based analysis. Christopher J.D. Wallis

288

Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160). Toni K. Choueiri

289

Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study. Daniel Peter Petrylak

290

Epidermal growth factor receptor (EGFR) targeted photoimmunotherapy (PIT) for the treatment of EGFR expressing bladder cancer. Reema Railkar

291

Quality of life (QL) of patients (pts) treated for muscle invasive bladder cancer (MIBC) with radiotherapy (RT) +/- chemotherapy (CT) in the BC2001 trial (CRUK/01/004): Analysis of impact of treatment at an individual level. Robert Anthony Huddart

292

A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors. Andrea B. Apolo

293

Small cell carcinoma of the bladder (SCCB): Clinical, histopathologic, and genomic predictors of clinical outcomes. MinYuen Teo

294

Association of treatment facility case volume with survival in patients undergoing radiotherapy/chemoradiotherapy for muscle-invasive bladder cancer: An analysis of the National Cancer Database. Amishi Bajaj

295

Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers to reveal discordant genomic and transcriptomic events and unique therapeutic opportunities. Daniel H. Hovelson

296

Clinical destiny of indeterminate pulmonary nodules in patients undergoing radical cystectomy for urothelial carcinoma of the bladder. David B. Cahn

297

Outcome of BC2001 patients (CRUK/01/004) who received neoadjuvant chemotherapy prior to randomization to chemo-radiotherapy (cRT) versus radiotherapy (RT). Syed A. Hussain

298

Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma. Bishoy Faltas

299

DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC). Matt D. Galsky

300

A hypoxia transcriptomic signature to predict benefit from hypoxia-modifying treatment for muscle-invasive bladder cancer patients. Ananya Choudhury

301

Next generation sequencing of non-muscle invasive bladder cancer to reveal potential biomarkers and rational therapeutic targets. Eugene J. Pietzak

302

An oral methionine aminopeptidase II inhibitor for high-risk non-muscle invasive bladder cancer relapsed after intravesical therapies: Update of a phase II trial. Dingwei Ye

303

Characterizing the costs of complications after cystectomy: Can we target the primary drivers? Matthew Mossanen

304

Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma. Ross Erik Krasnow

305

Investigation on relationships between reduction of cisplatin and anticancer effects in patients with bladder cancer. Yasuyoshi Miyata

306

Results of the GETUG-AFU 19 trial: A randomized phase II study of dose dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) with or without anti-epidermal growth factor receptor (EGF-R) monoclonal antibody panitumumab (PANI) in advanced transitional cell carcinoma (ATCC). Stephane Culine

307

Association of prior pelvic radiation with long-term oncologic outcomes following radical cystectomy. Harras B. Zaid

308

Second primary lung cancer in the United States: 1992–2008. Nicholas Donin

309

Comparison of genomic alterations in bladder urothelial tumors with and without telomerase reverse transcriptase promoter mutation using a next-generation sequencing assay. Sumit Isharwal

310

Does liposomal bupivacaine use intraoperatively decrease postoperative narcotic use in radical cystectomy patients? Janet Baack Kukreja

311

Association of age with utilization of radical cystectomy for high-grade nonmuscle invasive bladder cancer: Results from the National Cancer Database. William P. Parker

312

A phase I trial for the use of intravesical cabazitaxel, gemcitabine, and cisplatin (CGC) in the treatment of BCG-refractory nonmuscle invasive urothelial carcinoma of the bladder. Guarionex Joel DeCastro

313

Association of chemotherapy regimen with venous thromboembolic risk in patients with urothelial tract cancer. Jorge Ramos

314

Resection margins after radical cystectomy at academic versus community cancer centers. Kyle Scarberry

315

Outcomes and tolerability of selective bladder preservation by combined modality therapy for invasive bladder cancer in elderly patients. David Tomoaki Miyamoto

316

18F-FDG-PET/CT imaging to assess response to treatment with cabozantinib at 4 weeks versus 8 weeks of therapy in patients (pts) with metastatic urothelial carcinoma (mUC). Nicole N. Davarpanah

317

Cross-sectional evaluation of long-term bowel issues after radical cystectomy. Marie C Hupe

318

Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC). Gary D. Steinberg

319

Treatment patterns and economic burden of illness in patients with advanced bladder cancer receiving second-line therapy. Sumati Rao

320

Neoadjuvant vascular targeted photodynamic therapy in urothelial cancer: Preclinical data. Barak Rosenzweig

321

Examining gemcitabine and docetaxel for recurrent NMIBC. Niv Milbar

322

Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Outcomes by prior therapy. Jose Luis Perez-Gracia

323

Association of presurgery neutrophil-to-lymphocyte ratio with survival outcomes in patients with urothelial carcinoma treated without neoadjuvant chemotherapy and with radical cystectomy. Janet Baack Kukreja

324

A genome-wide query of somatic copy number alterations to predict lymph node metastases and survival in patients with muscle-invasive bladder cancer. Karla Lindquist

325

Molecular subtyping of metastatic urothelial bladder cancer. Charlotte Ackerman

326

Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132). Scott T. Tagawa

327

Assessing bone response to cabozantinib in patients (pts) with metastatic urothelial carcinoma (mUC) using 18F-Sodium Fluoride (NaF) PET/CT. Jeffrey Lin

328

Effect of green tea polyphenol on changes in cancer-related factors in a mouse model of bladder cancer. Tomohiro Matsuo

329

Avelumab in patients with metastatic urothelial carcinoma: Pooled results from two cohorts of the phase 1b JAVELIN Solid Tumor trial. Manish R. Patel

330

Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial. Nawar Hanna

331

Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis. Abhishek Tripathi

332

Effect of defective ERCC2 on cisplatin and ionizing radiation (IR) sensitivity in bladder cancer cells. Qiang Li

333

Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy. Petros Grivas

334

A chemically-modified miR-21 inhibitor (ADM-21) as a novel potential therapy in bladder cancer. Alexandra Drakaki

335

External validation and optimization of international consensus clinical target volumes for adjuvant radiation in bladder cancer. Abhinav V. Reddy

336

Perioperative and readmission rates in open and robotic assisted radical cystectomy: A National Cancer Database analysis. Kaitlin E. Kosinski

337

Phase I/Ib study of enzalutamide and gemcitabine and cisplatin in bladder cancer. Shilpa Gupta

338

Thrombo-embolic events (TEE) during neoadjuvant chemotherapy for muscle invasive bladder cancer. Syed A. Hussain

339

Measuring and improving symptom burden in radical cystectomy patients undergoing traditional care compared to enhanced recovery. Janet Baack Kukreja

340

Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) versus single agent and doublet chemotherapy (CT). Andrea Necchi

341

Efficacy of mycobacterium phlei cell wall-nucleic acid complex (MCNA) in BCG-unresponsive patients. Roger Li

342

The impact of MRE11 in nuclear to cytoplasmic ratio on outcomes in muscle invasive bladder cancer an analysis of NRG/RTOG 8802, 8903, 9506, 9706, 9906, and 0233. Anthony Martin Magliocco

343

Patient derived xenografts of upper tract urothelial carcinoma: A potential tool for personalized medicine. Kwanghee Kim

344

Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase II study. Andrea Necchi

345

Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival. Gregory Russell Pond

346

Difference in toxicity reporting between patients and clinicians during systemic chemotherapy for urothelial carcinoma. Shingo Hatakeyama

347

Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway. Alan Haruo Bryce

348

A multicohort phase I study of ramucirumab (R) plus pembrolizumab (P): Interim safety and clinical activity in patients with urothelial carcinoma. Daniel Peter Petrylak

349

Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder. Sumanta K. Pal

350

Sarcopenia as a useful predictor of postoperative complications following radical cystectomy: An assessment of preoperative CT scans. Martin Jp Hennig

351

Association of preoperative neutrophil-to-lymphocyte ratio with survival outcomes in patients undergoing radical cystectomy, regardless of neoadjuvant chemotherapy status. Janet Baack Kukreja

352

Cell-free tumor DNA and TERT promoter mutations in bladder cancer. Franklin W. Huang

353

Targeting ERBB2 mutations in urothelial carcinoma. Francois Audenet

354

Survival for patients with residual tumor at radical cystectomy following chemotherapy: A matched analysis to cystectomy-only patients. Bimal Bhindi

355

Evaluation of monocytic myeloid-derived suppressor cell (M-MDSC) frequency in patients with metastatic urothelial carcinoma (mUC). Samuel Funt

356

Flavoperidol as a novel therapeutic agent for bladder cancer. Reema Railkar

357

Prognostic value of PD-1 and PD-L1 expression in patients with high-grade urothelial carcinoma of the upper urinary tract. Laura-Maria Krabbe

358

Glucose metabolism and bladder cancer. Eugene K. Lee

359

Discerning predictors for gender differences in survival outcomes for patients treated for bladder cancer. Preston Kerr

360

Molecular characterization of urothelial carcinoma of bladder and upper urinary tract. In Gyu Hwang

361

Assessment of blood and tissue myeloid derived suppressor cells (MDSC), clinicopathologic factors, and treatment response in urothelial carcinoma (UC) patients (pts) undergoing surgery. Moshe Chaim Ornstein

362

Outcomes and survival in nonbilharzial pure squamous cell bladder cancer in patients undergoing curative radical cystectomy. Janet Baack Kukreja

363

Association of perioperative venous thromboembolism with long-term oncologic outcomes following radical cystectomy. Harras B. Zaid

364

Prescribing preferences of U.S. oncologists for patients (Pts) with metastatic urothelial carcinoma (mUC) at first recurrence: Impact of novel agents. Maria L. Lankford

365

Clinical and pathological outcomes for patients with T1HG bladder cancer managed with upfront cystectomy with or without neoadjuvant chemotherapy and the impact of the MDACC high-risk features. Michael J. Metcalfe

366

The effect of adjuvant chemotherapy for patients with adverse pathology after neoadjuvant chemotherapy for muscle invasive bladder cancer. William P. Parker

367

Increased utilization of advanced imaging technology and its economic impact for patients diagnosed with bladder cancer in the United States. Christopher David Kosarek

368

Adjuvant radiotherapy use after radical cystectomy in muscle-invasive bladder cancer: A survey of U.S. radiation oncologists. Abhishek Ashok Solanki

369

The prognostic utility of hemoglobin and lymphocytopenia in bladder-sparing therapy. Michael Drumm

370

Lynch syndrome-associated upper tract urothelial cancer: Assessment of clinical screening criteria and tissue-based point of care testing. Michael J. Metcalfe

371

Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB). Guru Sonpavde

372

Kent experience of radical chemoradiotherapy for muscle invasive bladder cancer. Jessica Gough

373

Identification of molecular biomarkers of cisplatin-based chemosensitivity in patients undergoing neoadjuvant chemotherapy for muscle-invasive bladder cancer. Paras Hemant Shah

374

Comprehensive genomic characterization of upper tract urothelial carcinoma (UTUC). Tyler J. Moss

375

Systemic therapy and overall survival trends in patients with non-urothelial histologic variants of muscle invasive bladder cancer undergoing radical cystectomy. Shreyas Joshi

376

High responses to chemotherapy in patients with metastatic urothelial cancer (MUC) after frontline immunotherapy. Bernadett Szabados

377

Dissecting the genomic landscape of metastatic bladder cancer using circulating tumor DNA. Werner J. Struss

378

Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC). Sumati Gupta

379

Young patients with bladder cancer: Outcomes from the National Cancer Database. Samuel L Washington

380

Humanized mice (humice) carrying patient-derived xenograft (PDX) as a platform to develop immunotherapy in bladder cancer (BCa). Chong-xian Pan

381

Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC). Vadim S. Koshkin

382

Intratumoral heterogeneity of ERBB2/HER2 expression in micropapillary urothelial carcinoma. Sumit Isharwal

383

Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC). Margaret K. Callahan

384

Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients. Sumati Gupta

385

Patient selection using novel RNA-based approaches: Early experience from a phase I study with the pan-FGFR inhibitor BAY 1163877 in patients with urothelial bladder cancer. Markus Joerger

386

Characterization of POLE-mutated (POLE+) urothelial carcinoma of the bladder and urinary tract (UC). MinYuen Teo

387

The impact of peri-operative chemotherapy for patients with lymph node-positive urothelial cancer. Jeenan Kaiser

388

Neoadjuvant chemotherapy for elderly patients with locally advanced disease: Are we doing enough? Andres Correa

389

Cisplatin-based neoadjuvant chemotherapy (NAC) in bladder cancer patients (Pts) with borderline renal function: Implications for clinical practice. Vadim S. Koshkin

390

Impact of histologic subtype on bladder cancer outcome. Samuel L Washington

391

Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis. Fumitaka Shimizu

392

ATM/RB1 mutations to predict shorter overall survival (OS) in bladder cancer. Ming Yin

393

Premature clinical trial discontinuation in all and genitourinary (GU) cancers in the era of immune checkpoint inhibitors (ICI). Monica Khunger

394

Preoperative risk factors predicting postoperative complications in radical cystectomy for bladder cancer. Derek Jensen

395

Treatment patterns and outcomes in metastatic bladder cancer in community oncology settings. Maxine Fisher

396

Tumor mutation burden to predict progression in high-risk non-muscle invasive bladder cancer. Joshua Meeks

397

Combination checkpoint immunotherapy and cytotoxic chemotherapy: Pembrolizumab (Pembro) plus either docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer. Primo Lara

398